Journal article
Prescription Patterns and Testosterone Concentrations Achieved With AndroForte 5% Testosterone Cream in Transgender and Gender Diverse Individuals
BJ Nolan, S Zwickl, P Locke, S Simpson, L Li, JD Zajac, AS Cheung
Journal of Sexual Medicine | Published : 2022
Abstract
Background: Masculinizing hormone therapy with testosterone is used to align an individual's physical characteristics with their gender identity in trans and gender diverse individuals. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically administered. 100 mg AndroForte 5% testosterone cream is the recommended starting dose in hypogonadal cisgender men but there are no data evaluating the use of AndroForte 5% testosterone cream in gender-affirming hormone therapy regimens. Aim: To assess the prescription patterns and serum total testosterone concentrations achieved with AndroForte 5% testosterone cream in trans and gender diverse individuals. M..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
No funding was received for this project. BJN is a recipient of an Australian Government National Health and Medical Research Council Postgraduate Scholarship (#2003939). ASC is supported by a National Health and Medical Research Council Early Career Fellowship (#1143333) atnd Investigator Grant (#2008956).